Frequently Asked Questions
In this section you can find answers to frequently asked questions about Fagron
Fagron’s business
Pharmaceutical compounding involves the creation of non-patent protected or unregistered pharmaceutical preparations by, or at the request of community or hospital pharmacies, based on a doctor’s prescription. This results in the preparation of not commercially available, personalized medicine to meet a patient’s specific needs. Fagron is active in the entire value chain of pharmaceutical compounding and offers a full range of products and services to its customers.
Pharmaceutical compounding enables a prescriber to offer patients a personalized treatment that is not standardly available, suited to a patient’s specific requirements. One can think of a personalized administration form or dosage when a patient is not able to use the standard available administration forms of existing medications due to, for example, age, problems with swallowing, or allergies. In addition, an alternative dosage form, such as a topical dosage in the form of a cream, can reduce side effects and the potential for addiction and release the medication directly at the location of the condition, for example when treating pain. Fagron is active in the entire value chain of pharmaceutical compounding and offers a full range of products and services to its customers.
Fagron is active in the regions EMEA (Europe, Middle East, and Africa), Latin America and North America.
Fagron is present in 20 countries: Belgium, Brazil, China, Colombia, Croatia, Czech Republic, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Mexico, the Netherlands, Poland, South Africa, Spain, United Kingdom, and United States of America.
Fagron is active in 34 countries (i.e. countries where Fagron realized sales of at least €250k in 2023): Austria, Australia, Belgium, Bosnia Herzegovina, Brazil, Canada, Colombia, Croatia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Israel, Italy, Luxembourg, Mexico, the Netherlands, Norway, Poland, Portugal, Romania, San Marino, Serbia, Slovenia, Slovakia, South Africa, Spain, Switzerland, Turkey, United Kingdom, and United States.
Fagron has been active in Europe since its establishment in 1990. Fagron operates in 29 countries in the EMEA region and offers Brands & Essentials in these countries. Additionally, Fagron offers Compounding Services in Belgium, Czech Republic, Israel, the Netherlands, and South Africa. Fagron has a presence in China as it procures a large part of its raw materials from China. Of Fagron’s total revenue around 37% is generated in the EMEA region.
In Latin America, Fagron is present in Brazil (Brands & Essentials), in Colombia (Compounding Services) and Mexico (Brands & Essentials). Brazil is the largest market for Fagron in Latin America, representing over 80% of the region’s revenue. Of Fagron’s total revenue over 20% is generated in the Latin America region.
In North America, Fagron is active in Brands & Essentials, and Compounding Services. Of Fagron’s total revenue around 40% is generated in the North America region.
Fagron has three segments: Essentials, Brands, and Compounding Services.
Fagron started supplying pharmaceutical grade raw materials to community and hospital pharmacies for pharmaceutical compounding. With an increase in the demand and our continuous effort to offer value to compounding pharmacies, we have expanded the product line with equipment and supplies. Today, we support pharmacists in EMEA, Latin America and North America and enable them to compound safe and high-quality products, while also optimizing the compounding process with our equipment and packaging. Our portfolio of Essentials includes pharmaceutical raw materials, equipment, packaging, and supplies required for pharmaceutical compounding.
Of Fagron’s total revenue almost 49% is generated in our Essentials segment.
Because pharmacies and pharmaceutical compounding are becoming more regulated and quality requirements are becoming stricter, there is a greater need for semi-finished products and pharmaceutical grade vehicles that improve quality and reduce the workload for pharmacists. Under our Brands segment, Fagron develops new and innovative vehicles and equipment for pharmaceutical compounding in close cooperation with pharmacists, physicians, and universities. Our Brands’ products include emulsions, powder mixtures, creams, complete concepts, and equipment developed by Fagron. Furthermore, our Brands segment includes Fagron Genomics which specializes in the development, production, and marketing of innovative genetic tests. The use of these tests enables the prescription of the most suitable personalized therapy, particularly in lifestyle and preventative healthcare.
Of Fagron’s total revenue almost 17% is generated in our Brands segment.
Next to pharmaceutical raw materials and vehicles, Fagron began delivering non-sterile ready-to-dispense compounded medicine to pharmacies in order to support them further. Prompted by increasingly stricter regulations and focus on quality and efficiency, pharmacies are also outsourcing their sterile compounding more and more. Fagron supplies sterile ready-to-administer medicines to hospital pharmacies in those countries where the regulation allows this. These sterile and non-sterile compounded products, which meet the specific needs of patients, are sold under the Compounding Services segment. We compound products in our compounding facilities in Belgium, Colombia, Czech Republic, Israel, the Netherlands, South Africa, and United States of America. Compounding Services uses the raw materials from Essentials and the vehicles from Brands for its compounding activities.
Formulary, a global initiative of Fagron, offers pharmacists and prescribers a broad range of customized formulas linked to the indications for which they can be prescribed. Prescribers can find an indication and formulas that suits the personal needs of the patient. Pharmacists can find customized formulas with the methods of compounding. Formulary represents a scientifically evidence-based selection of formulas for customized medication and is available free to all prescribers and pharmacists.
Of Fagron’s total revenue almost 35% is generated in our Compounding Services segment.
What is Fagron Academy?
Fagron operates within a knowledge-intensive niche market, making it essential that the key links between us and the patient – prescribers and pharmacists – possess in-depth knowledge of the latest developments in pharmaceutical compounding, as well as the products and services we offer. We inform and train prescribers and pharmacists through our local and global Fagron Academy platforms. Through knowledge sharing, training, courses, and educational programs, Fagron Academy enhances the compounding expertise and skills of prescribers and pharmacists. Fagron collaborates with universities worldwide to develop academic programs and offers extensive training on topics such as compounding techniques, material use, dosage forms, and quality and safety procedures. The core pillars of Fagron Academy are:
- Formulary provides pharmacists and prescribers with a wide selection of customized formulas tailored to specific indications. Prescribers can easily find formulas that meet the unique needs of their patients, while pharmacists can access detailed compounding methods for each formula. Formulary offers a scientifically evidence-based collection of formulas designed for personalized medication, available at no cost to all prescribers and pharmacists.
- Video Platform serves as an educational hub for personalized medicine, specifically designed for compounders, prescribers, and medical professionals. Our platform bridges the gap between prescription and compounding in personalized treatments, offering comprehensive training for both compounders and prescribers/medical doctors with a focus on personalized care.
- Library offers a convenient way to explore the scientific research behind Fagron’s products. This platform features a growing collection of peer-reviewed studies on topics such as safety, compatibility, and efficacy. Users can filter articles by product or date, view key takeaways, and access full publications through the original journal links.
Fagron Genomics and GX Sciences specialize in the development, production, and marketing of innovative genetic tests. Understanding this information allows healthcare providers to define better treatments that may improve the therapeutically outcome for a specific patient. Fagron Genomics provides pharmacogenetics and diagnostic molecular analysis for healthcare professionals. Our genetic tests can identify genetic variations, based on which the prescriber is able to prescribe the most suitable and effective personalized therapy for a patient, particularly in lifestyle and preventative healthcare. Fagron Genomics is part of our Brands segment.
Fagron’s customers are pharmacists, hospitals, clinics, prescribers, patients, wholesalers, and industry. Pharmacists, hospitals, clinics, prescribers, and patients account for just over 80% of our total customer base, wholesalers, and the industry for around 20%.
Fagron is the global leader in pharmaceutical compounding. As a vertically integrated player, Fagron is active in the entire value chain of pharmaceutical compounding. Fagron is unique in offering a full range of products and services and doing so globally.
In the countries where Fagron operates, we compete mostly with local players which are generally either active in our Essentials & Brands segments, or in our Compounding Services segment.
Information on this page was most recently updated on 15 February 2024.